I reported previously (see here) on the AJOVY fremanezumab migraine treatment from Israel’s Teva. The US FDA has just given approval for AJOVY – the only anti-CGRP treatment for the prevention of migraine.  About 40% of migraine sufferers may be … Continue reading →

Israel’s Teva has been granted fast-track status for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody developed for the preventive treatment of migraine. It also applies to the prevention of cluster headaches, which are similar to migraines in symptoms. http://www.jewishpress.com/news/us-news/teva-wins-fda-application-acceptance-for-fremanezumab/2017/12/18/

Israel’s Teva has reported positive results from Phase III trials of its chronic migraine treatment fremanezumab.  Patients experienced statistically significant reduction in the number of moderate severity headache days vs the placebo. FDA approval is expected by end 2017. http://www.globes.co.il/en/article-teva-reports-positive-phase-iii-migraine-drug-trial-results-1001190672